HEMACARE INCREASES REVENUES, DEEPENS LOSSHemaCare Corp. (NASDAQ:HEMA) of Sherman Oaks, Calif.Fourth-quarter results included an estimated 21 percentincrease in therapeutic hemapheresis revenues to $996,000and an estimated 13 percent increase in specialty plasmarevenues to $270,000 from MD Laboratories Inc. HemaCareLaboratories Inc., a division initiated in April 1990, continuesto exceed revenue projections, but is not expected to becomeprofitable until at least the middle of this year.

Fourth quarter ended Dec. 31

(Figures in thousands except per-share data.)

1990 1989 Percent change

Revenues $2,687 1,589 +69Extraordinary item 300 0 300Net income (loss) (492) 137 n/aNet income per share (loss) (.15) .04 n/aOutstanding shares 3,356 3,409 -2

Year ended Dec. 31

(Figures in thousands except per-share data.)

1990 1989 Percent change

Revenues $8,471 5,769 +47Extraordinary item 300 0 +300Net income (loss) (1,015) 471 n/aNet income per share (loss) (.30) .14 n/aOutstanding shares 3,356 3,419 -2

IG LABORATORIES INCREASES REVENUES, CUTS LOSS

IG Laboratories Inc. (NASDAQ:IGLI) of Framingham, Mass., saidgrowing revenues reflect increased sales from the company'sNortheast operations and additional revenues from its Mid-Atlantic and Sourtheast operations, both acquired during thefourth quarter of 1990. The reduced loss reflects increases inservice revenue and improved gross margins, the companysaid.

Fourth quarter ended Dec. 31

(Figures in thousands except per-share data.)

1990 1989 Percent change

Revenues $2,281 329 +600Net income (loss) (471) (609) +23Net income per share (loss) (.08) - n/aOutstanding shares 5,856 - n/a

Year ended Dec. 31

(Figures in thousands except per-share data.)

1990 1989 Percent change

Revenues $4,358 795 +448Net income (loss) (2,075) (2,352) +12Net income per share (loss) (.57) - n/aOutstanding shares 3,654 - n/a

(c) 1997 American Health Consultants. All rights reserved.